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Abstract
Background: Bisphosphonates are indicated in the prevention and treatment of osteoporosis.
However, bone mineral density (BMD) continues to decline in up to 15% of bisphosphonate users.
While randomized trials have evaluated the efficacy of concurrent bisphosphonates and vitamin D,
the incremental benefit of vitamin D remains uncertain.
Methods: Using data from the Canadian Database of Osteoporosis and Osteopenia (CANDOO),
we performed a 2-year observational cohort study. At baseline, all patients were prescribed a
bisphosphonate and counseled on vitamin D supplementation. After one year, patients were
divided into two groups based on their response to bisphosphonate treatment. Non-responders
were prescribed vitamin D 1000 IU daily. Responders continued to receive counseling on vitamin
D.
Results: Of 449 patients identified, 159 were non-responders to bisphosphonates. 94% of patients
were women. The mean age of the entire cohort was 74.6 years (standard deviation = 5.6 years).
In the cohort of non-responders, BMD at the lumbar spine increased 2.19% (p < 0.001) the year
after vitamin D was prescribed compared to a decrease of 0.55% (p = 0.36) the year before. In the
cohort of responders, lumbar spine BMD improved 1.45% (p = 0.014) the first year and 1.11% (p
= 0.60) the second year. The difference between the two groups was statistically significant the first
year (p < 0.001) but not the second (p = 0.60). Similar results were observed at the femoral neck
but were not statistically significant.
Conclusion: In elderly patients with osteoporosis not responding to bisphosphonates, vitamin D
1000 IU daily may improve BMD at the lumbar spine.
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Background
Osteoporosis is a skeletal disease characterized by low
bone mass and microarchitectural deterioration of bone
tissue, which consequently increase bone fragility and the
susceptibility to fracture [1]. Osteoporosis strikes one in
four women over the age of 50 years [2]. There are over 20
000 osteoporosis-related hip fractures in Canada annual-
ly. The mortality associated with hip fractures exceeds
25% at one year, with nearly one quarter of survivors re-
quiring institutionalization in a long-term care facility [3].
Bisphosphonates are indicated in the prevention and
treatment of Osteoporosis, as they are potent inhibitors of
bone resorption. Clinical trials in primary Osteoporosis
have provided conclusive evidence that in most patients
therapy with this class of drug leads to improvement in
bone mass and a reduction in subsequent fractures [4–
19].
Despite treatment with a bisphosphonate, bone mineral
density (BMD) continues to decline in up to 15% of etid-
ronate users and 5% of alendronate users [4,13]. As a con-
sequence, vitamin D may be recommended as adjunctive
therapy in addition to increased calcium intake in those
who do not to respond to bisphosphonate therapy. The
vitamin D metabolite 1,25-dihydroxy vitamin D (calcitri-
ol) is required for the active intestinal absorption of calci-
um and plays in concert with the parathyroid hormone
(PTH), an important role in releasing calcium from bone
and regulating plasma calcium [20]. Vitamin D deficiency
is a risk factor for Osteoporosis [21–24]. Moreover, daily
supplementation with vitamin D and calcium has been
shown to reduce bone loss at the spine and femoral neck
as well as the prevalence of non-vertebral fractures [25–
27].
While a large number of randomized trials have evaluated
the efficacy of bisphosphonate treatment with concurrent
vitamin D (in doses varying between 125 to 500 IU)
[4,16,28–31], the incremental benefit of vitamin D in pa-
tients taking bisphosphonates is uncertain. Therefore,
from data that were collected from the Canadian Database
of Osteoporosis and Osteopenia (CANDOO) patients
[32], we performed a 2-year observational cohort study to
determine the impact of prescribed vitamin D supple-
ments on BMD in osteoporotic patients who had not re-
sponded to bisphosphonates and calcium therapy alone.
Methods
Study Design
Data were obtained from an analysis of computer-based
patient records registered in CANDOO. The CANDOO
database was designed to prospectively compile compre-
hensive clinical data in a cohort of patients seen in special-
ized tertiary care referral centres in Hamilton, Ontario,
Canada. Data are aggregated using anonymous patient
identifiers into a centrally maintained, fully keyed and en-
coded relational database. CANDOO contains data re-
garding patient demographics, medications and side
effects, female reproductive history, diet and quality of
life, BMD measurements, fracture history, and laboratory
investigations. A patient record is generated at each con-
sultation and at each follow-up visit. In addition, at each
visit, patients received counseling about exercise, diet and
supplementation with calcium and vitamin D.
For the current analysis the database was searched for pa-
tients attending a single clinic from January 1990 to No-
vember 1997 (baseline). Bisphosphonate therapy was
given as either cyclical etidronate (400 mg/d for 14 days
followed by 76 days of 500 mg/d of elemental calcium) or
alendronate (10 mg/day). Risedronate was not available
in Canada at the time of the study. A total of 449 patients
formed this cohort. These patients were then followed for
two years. At the first follow-up visit (at approximately
one year) patients were divided into two treatment groups
depending on their response to bisphosphonate therapy
in the preceding year. Group 1 (BISVITD) comprised
those who did not respond to bisphosphonate therapy in
the preceding year. In this cohort of patients, concomitant
therapy with vitamin D (1000 lU/d) was prescribed. Treat-
ment non-responders were defined as patients who had a
negative change in lumbar spine and femoral neck BMD
from baseline measurements or experienced an incident
fracture while on therapy. Group 2 (BIS) comprised those
who responded to bisphosphonate therapy in the preced-
ing year and were not taking vitamin D supplements. Re-
sponders were defined as patients who had a positive
change in lumbar spine and femoral neck BMD from
baseline and did not sustain an incident fracture while on
therapy. Both groups were then followed for an additional
year (second follow-up visit) (figure 1).
Measurements
BMD measurements were taken at baseline, the first fol-
low-up visit and the second follow-up visit using Dual-En-
ergy X-ray Absorptiometry (DXA) with Lunar DPX-alpha
(Lunar Corporation, Madison, Wisconsin). The coeffi-
cient of variation for measurements reported for this in-
strument is 68% of repeat measurements falling within 1
standard deviation. All three measurements for each indi-
vidual patient were performed using the same device.
Baseline data extracted for analysis include age; sex; body
mass index (BMI); bisphosphonate type; prior or current
treatment with ovarian hormones; treatment with fluo-
ride or calcitonin; risk factors for osteoporosis including
smoking, alcohol intake, prior fractures and exposure to
corticosteroids (inhaled or systemic), anti-seizure medica-
tion, thyroid hormone therapy, chemotherapy or im-
mune suppressants; dietary and supplemental calciumBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/6
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intake; and serum calcium, phosphorus, and alkaline
phosphatase (ALP). 25-hydroxy vitamin D (25(OH)D)
levels were obtained through blood samples collected
within 30 days of clinic visit and sent to a central hospital
laboratory. 25(OH)D levels were determined using a radi-
oimmunoassay kit (normal range 16–74 ng/mL; devel-
oped by Nichols Institute Diagnostics, California).
Incident fractures were registered based on patient re-
sponse to an item ("How many new fractures have you
had since your last visit?) from the CANDOO question-
naire. Incident vertebral fractures may or may not have
been confirmed by x-ray. Unblinded clinical judgment
was used to determine the existence of a vertebral fracture
on x-ray. Incident non-vertebral fractures included the an-
kle, arm, clavicle, elbow, foot, heel, hand, hip, knee, leg,
nose, pelvis, rib, shoulder, sacrum, and wrist.
Statistical Analysis
Differences in baseline characteristics were analyzed using
the Students' t-test. Analysis of covariance was performed
to test for differences between the groups in the mean per-
cent change from baseline to the first and second follow-
up visits in BMD at the lumbar spine and femoral neck.
Covariates included in the analyses were those variables
that were significantly different between groups at base-
line. One-way analysis of variance was performed to test
for mean percent changes within groups in BMD at the
lumbar spine and femoral neck. The relationship between
serum 25(OH)D and response to vitamin D was analyzed
with linear regression. All analyses used a two-tailed alpha
level of 5% and were performed with SPSS Version 8.0
(SPSS Inc).
Results
Patient characteristics are presented in Table 1. Overall,
449 patients were identified, 159 patients received a bi-
sphosphonate and vitamin D while 290 received bisphos-
phonate therapy. Due to missing data, lumbar spine BMD
was available for 155 (BISVITD) and 282 (BIS) patients,
whereas femoral neck BMD was available for 156 and 280
patients from each treatment group, respectively. The 12
patients for whom lumbar spine data were missing had a
higher BMI (29.1 vs. 25.9 kg/m2, p = 0.020) and con-
sumed more hypnotics (33% vs 10%, p = 0.030) as com-
pared with patients that had complete lumbar spine data.
Furthermore, the 13 patients with missing femoral neck
data were more likely to have received systemic steroids
(46% vs 18%, p < 0.010), tamoxifen (10% vs 3%, p <
0.001) and fluoride (30% vs 8%, p = 0.005); less likely to
receive anti-epileptics (10% vs 0.9%, p = 0.006); and had
a higher serum ALP than the group with complete femoral
neck data (120.8 vs 90.9 mmol/L, p = 0.018).
Of the patients evaluated in the study, 94% were women.
The cohort was relatively elderly, with a mean age of 74.6
years (standard deviation = 5.6 years). There were statisti-
cally significant differences between the groups at baseline
with respect to age, BMI, type of bisphosphonate, calcium
supplementation and lumbar BMD. There was no differ-
ence in total calcium intake. There were significant differ-
ences in exposure to immune suppressing and lipid
lowering agents, though 0.7% and 1% of all patients re-
spectively had received such medications. Serum
25(OH)D levels were not different between the groups,
but were available for 51 treatment and 115 control pa-
tients only (Table 1).
Lumbar Spine BMD
The changes in lumbar spine BMD over the 2-year trial are
shown in Figure 2. Prior to the initiation of vitamin D, at
Figure 1
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the first follow-up visit, lumbar spine BMD declined from
baseline measurements by 0.55% (p = 0.363) in the BIS-
VITD group and improved 2.19% in the BIS group (p <
0.001). At the second follow-up visit, lumbar spine BMD
increased from the first follow-up measurement by 1.45%
(p = 0.014) in the BISVITD group and by 1.11% (p <
0.001) in the BIS group. The difference between the two
treatment groups was statistically significant at the first
follow-up (p < 0.001) but not at the second (p = 0.595)
after adjusting for confounding variables.
Femoral Neck BMD
The changes in femoral neck BMD over the two-year study
are depicted in Figure 3. Prior to the initiation of vitamin
D, at the first follow-up visit, femoral neck BMD declined
by 1.09% (p = 0.062) in the BISVITD group and increased
by 0.43% (p = 0.266) in the BIS group. At the second fol-
low-up visit, femoral neck BMD increased from the first
follow-up measurement by 1.15% (p = 0.094) in the BIS-
VITD group compared to a decline of 0.34% (p = 0.369)
in the BIS group. The difference between the two treat-
ment groups was not significant at either the first or the
second follow-up (p = 0.299 and p = 0.157, respectively),
after adjusting for confounding variables.
Effect of baseline serum 25(OH) D
In the treatment group, regression analysis did not dem-
onstrate an association between serum 25(OH)D and
change in lumbar spine or femoral BMD after vitamin D
was prescribed.
Discussion
BMD continues to decline in 5 to 15% of patients with os-
teoporosis despite treatment with etidronate or alendro-
nate [4,13]. These patients often receive supplementation
with vitamin D, though evidence to support the value of
this intervention has been lacking. In our analysis of pa-
tients not responding to stable bisphosphonate therapy,
we demonstrated that the concurrent use of vitamin D
(1000 lU/d) was associated with an increased lumbar
spine (1.45%) and femoral neck BMD (1.15%) in those
who had previously experienced a decline in BMD while
on bisphosphonate therapy alone. In addition, no signif-
icant differences were found between those who initially
responded to bisphosphonate therapy versus non-re-
sponders following treatment. This suggests that vitamin
D supplementation may be an effective concurrent medi-
cation in those who have not responded to bisphospho-
nate therapy.
The power of the study to detect a 1.15% (standard devi-
ation= 4%) change in femoral neck bone density from
baseline to the second-follow-up visit in the 156 patients
was approximately 95%. The absence of a statistically sig-
nificant response to vitamin D at the femoral neck sug-
gests that the lumbar spine and femoral neck may respond
differently to vitamin D. Differences in bone density re-
sponse between the lumbar spine and the femoral neck
have been observed in other studies [33,34].
In this study, the improvement in BMD occurred despite
no significant difference in serum 25(OH)D levels be-
tween the two treatment groups at baseline, and no rela-
Table 1: Baseline Characteristics
BIS BISVITD P value
N 290 159 -
Age (years) (SD*) 75.1 (5.7) 73.6 (5.6) 0.011
Women 263 149 0.267
Body mass index (kg/m2) (SD*) 26.3 (4.9) 25.3(3.7) 0.024
Bisphosphonate
- Etidronate 89.3% 95.0% 0.042
- Alendronate 10.7% 5.0%
Years of bisphosphonates (SD*) 5.9 (2.4) 1 (0.0) 0.001
Calcium (mg/day)
- supplement 658.2 757.1 0.002
- dietary 635.3 609.9 0.586
- total 1266.0 1319.0 0.369
Previous exposure to
- estrogen 37.6% 30.4% 0.127
- fluoride 9.0% 8.8% 0.955
- calcitonin 1.7% 3.0% 0.330
Previous fracture 68% 69% 0.786
Weekly alcohol intake (ounces) 1.63 1.26 0.537
Smoking history 32% 35% 0.616
Corticosteroids
- systemic 19.7% 17.0% 0.488
- inhaled 12.4% 14.5% 0.539
Ever treated with
- non-steroidal anti-inflammatory 39.7% 35.2% 0.356
- thyroxin 12.6% 15.7% 0.393
β -blocker 6.6% 8.2% 0.523
- sedative-hypnotic 7.2% 6.3% 0.704
- thiazide 7.2% 6.3% 0.704
- calcium-channel blocker 1.0% 2.5% 0.227
- lipid-lowering agent 0.3% 2.5% 0.036
- anticonvulsants 0.7% 1.3% 0.541
- tamoxifen 0.7% 1.3% 0.295
- immunosuppressant 0.0% 1.9% 0.019
- chemotherapy 0.0% 0.0% -
Laboratory values
- 25(OH)D (ng/mL) 32.9 31.3 0.493
- ALP(IU/L) 90.7 94.0 0.474
- Calcium (mmol/L) 2.36 2.36 0.903
- Phosphorus (mmol/L) 1.13 1.14 0.539
Baseline BMD (g/cm2)
- lumbar spine 0.9287 0.8991 0.045
- femoral neck 0.7031 0.6850 0.081
*Standard DeviationBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/6
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tionship between baseline levels and response to
prescribed vitamin D was observed. The low baseline
25(OH)D is consistent with previous observations of vita-
min D deficiency in elderly persons [35], and suggests that
the observed increases in BMD may partially reflect im-
proved nutritional status.
The principal limitation of this observational study was
that patients were not randomized into their respective
treatment groups. The majority of patients in the interven-
tion group were selected based on declining BMD after
one year of treatment. Thus, differences between the
groups were found at baseline. In addition, as the treat-
ment group was defined by a decline in BMD after one
year, regression to the mean may partially explain the im-
provement in BMD measured at the second follow-up
[36]. The absence of blinding may have motivated pa-
tients not responding to bisphosphonates to adhere more
rigorously to recommended dietary and lifestyle recom-
mendations, confounding the effect on BMD attributed to
vitamin D. Finally, sample size limitations prevent gener-
alizability of the results to male patients and those receiv-
ing alendronate.
In summary, in elderly patients with osteoporosis who are
not responding to bisphosphonates, concomitant use of
vitamin D may improve BMD of the lumbar spine. Clear-
ly, the hypothesis that vitamin D improves BMD in pa-
tients receiving bisphosphonates needs to be verified in a
prospective controlled trial.
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